Skip to main content

Table 2 Medication at baseline in the four categories of body composition classified using A/G ratio

From: Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: a retrospective observational study

 

Normal (n = 187)

Sarcopenia (n = 171)

Obesity (n = 275)

Sarcopenic obesity (n = 83)

p value*

Insulin (%)

34

39

36

39

0.756

Sulfonylureas (%)

20

21

24

21

0.652

Metformins (%)

24

15

43

29

< 0.001

Alpha-GIs (%)

16

16

10

12

0.146

Glinides (%)

5

4

3

5

0.704

TZDs (%)

9

3

8

5

0.068

DPP4 inhibitors (%)

27

30

39

46

0.005

SGLT2 inhibitors (%)

1

0

1

1

0.631

GLP1-RAs (%)

2

2

4

1

0.581

ACEIs (%)

5

2

3

5

0.396

ARBs (%)

41

32

56

50

< 0.001

CCBs (%)

32

28

46

43

< 0.001

Alpha blockers (%)

1

1

3

0

0.122

Beta blockers (%)

11

8

11

18

0.129

Diuretics (%)

10

10

8

12

0.790

Statins (%)

47

31

54

40

< 0.001

Fibrates (%)

5

2

2

2

0.103

Ezetimib (%)

5

2

2

0

0.082

EPAs (%)

3

2

3

5

0.774

UA lowering agents (%)

8

8

15

13

0.029

Anti-platelet agents (%)

18

22

26

33

0.050

  1. ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers, CCBs, calcium channel blockers; DPP4, dipeptidyl peptidase 4; EPA, eicosapentaenoic acid; GIs, glycosidase inhibitors; GLP1-RA, glucagon-like peptide-1 receptors agonist; SGLT2, sodium-glucose cotransporter 2; TZDs, thiazolidinediones; UA, uric acid
  2. * Chi square test or Fisher’s exact test